Rapid Test Kit BD Veritor™ System Infectious Disease Immunoassay SARS-CoV-2

In stock
SKU
BD-256082
$1,080.00

(30 Tests per Kit)

Buy 20 kits or more get 5% OFF!

All product short-dated and expires January 7th, 2021. No returns or exchanges.

Features

  • The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is for use under an Emergency Use Authorization ONLY: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests
  • This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status
  • Positive results do not rule out bacterial infection or co-infection with other viruses
  • Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities
  • Negative results should be treated as presumptive, do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions
  • Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management
  • The BD Veritor System for Rapid Detection of SARS-CoV-2 is intended for use by trained clinical laboratory personnel specifically instructed and trained in the techniques of in vitro diagnostic procedures, and proper infection control procedures and individuals similarly trained in point of care settings
  • BD Veritor™ System for Rapid Detection of SARS-CoV-2 is a chromatographic digital immunoassay intended for the direct and qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasal swabs from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms

Product Specifications

Manufacturer # 256082
Brand BD Veritor™ System
Manufacturer BD Primary Care
Country of Origin Unknown
Application Rapid Test Kit
Contents (30) Single-use Test Devices, (30) Single-use Reaction Tubes, (30) Sterile Single-use Specimen Sampling Swabs, Positive SARS-CoV-2 Control Swab, Negative SARS-CoV-2 Control Swab, Instructions for Use, Quick Reference Card, Nasal Sampling Instructions
For Use With For use with the BD Veritor™ Plus Analyzer running Firmware version 5.4 or later
Number of Tests 30 Tests
Reading Type Machine Read
Sample Type Nasal Swab Sample
Storage Requirements Requires Refrigeration
Test Format Test Device
Test Method Chromatographic Digital
Test Name SARS-CoV-2
Test Type Infectious Disease Immunoassay
Time to Results 15 Minute Results
© 2019 Cliawaived, Inc. All Rights Reserved. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.